Silence Therapeutics plc
SLN Nasdaq
SEC CIK 1479615
Follow Silence Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$12.4M
+40.7% vs same quarter last year
EPS, diluted
−$0.08
+46.7% vs same quarter last year
Operating cash flow
−$12.8M
−17.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $559K | −$88.6M |
| FY24 | $43.3M | −$45.3M |
| FY23 | $31.6M | −$54.2M |
| FY22 | $21.7M | −$50.3M |
| FY21 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 61.5% | −16292.8% | −15851.5% |
| FY24 | 72.7% | −146.4% | −104.7% |
| FY23 | 59.3% | −203.5% | −171.4% |
| FY22 | 37.8% | −281.9% | −232.4% |
| FY21 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$62.3M |
| FY24 | −$67.9M |
| FY23 | −$49.5M |
| FY22 | −$57.2M |
| FY21 | - |
- Silence Therapeutics
- Healthcare median
Show the numbers
| Year | Silence Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −15851.5% | −30.6% |
| FY24 | −104.7% | −47% |
| FY23 | −171.4% | −58% |
| FY22 | −232.4% | −80.4% |
| FY21 | - | −71.8% |